无创诊断和评估非酒精性脂肪性肝炎研究进展*

doi:10.3969/j.issn.1672-5069.2019.02.038

Abstract

Abstract: Nonalcoholic fatty liver disease （NAFLD） includes a spectrum of diseases ranging from nonalcoholic fatty liver （NAFL） to nonalcoholic steatohepatitis （NASH）,cirrhosis and eventually to hepatocellular carcinoma （HCC）. NASH has an increased risk for advanced cirrhosis and HCC,so there has been an urgent need to accurately distinguish between NAFL and NASH and intervene its further development in early time. In recent years,many noninvasive diagnostic methods including serological markers and imaging examination were applied in clinical practice trying to replace liver biopsy. This article reviews the noninvasive diagnosis and evaluation of NASH.

Key words: Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Noninvasive diagnosis, Assessment

Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.

References

[1] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[2] Fazel Y,Koenig AB,Sayiner M,et al.Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism,2016,65(8):1017-1025.
[3] Marengo A,Jouness RI,Bugianesi E,et al.Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis,2016,20(2):313-324.
[4] Kleiner DE,Brunt EM,Van Natta M,et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41(6):1313-1321.
[5] Bedossa P,Poitou C,Veyrie N,et al.Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology,2012,56(5):1751-1759.
[6] Verhaegh P,Bavalia R,Winkens B,et al.Non-invasive tests do not accurately differentiate non-alcoholic steatohepatitis from simple steatosis:asystematic review and meta-analysis. Clin Gastroenterol Hepatol,2017 [Epub ahead of print].
[7] Alkhouri N,Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease:Are we there yet Metabolism,2016,65(8):1087-1095.
[8] Boga S,Koksal AR,Alkim H,et al.Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis(NASH) from non-NASH. Metab Syndr Relat Disord,2015,13(9):393-399.
[9] Kowdley KV,Belt P,Wilson LA,et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology,2012,55(1):77-85.
[10] Angulo P,George J,Day CP,et al.Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2014,12(7):1163-1169.
[11] Hagstrom H,Nasr P,Bottai M,et al.Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int,2016,36(11):1688-1695.
[12] Tsutsui M,Tanaka N,Kawakubo M,et al.Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol,2010,44(6):440-447.
[13] Aida Y,Abe H1,Tomita Y,et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med,2014,7(11):4191-4198.
[14] Alkhouri N,Alisi A,Okwu V,et al.Circulating soluble fas and fas ligand levels are elevated in children with nonalcoholic steatohepatitis. Dig Dis Sci,2015,60(8):2353-2359.
[15] Kamada Y,Akita M,Takeda Y,et al.Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One,2013,8(6):e66328.
[16] Kamada Y,Ono M,Hyogo H,et al.A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology,2015,62(5):1433-1443.
[17] Koo BK,Joo SK,Kim D,et al.Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2017 [Epub ahead of print].
[18] Liu X,Wang Y,Ming Y,et al.S100A9:A potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis. PLoS One,2015,10(5):e0127352.
[19] Qi S,Xu D,Li Q,et al.Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clin Chim Acta,2017,473:89-95.
[20] Gutierrezbuey G,Núnezcórdoba J M,Llaverovalero M,et al.Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes Eur J Intern Med,2017,41:74.
[21] Golabi P,Sayiner M,Fazel Y,et al.Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol,2016,10(1):63-71.
[22] Bedogni G,Bellentani S,Miglioli L,et al.The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol,2006,6(1):33.
[23] Otgonsuren M,Estep MJ,Hossain N,et al.Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis(NASH). J Gastroenterol Hepatol,2014,29(12):2006-2013.
[24] Schwenzer NF,Springer F,Schraml C,et al.Non-invasive assessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance. J Hepatol,2009,51(3):433-445.
[25] Park SH,Kim PN,Kim KW,et al.Macrovesicular hepatic steatosis in living liver donors:use of CT for quantitative and qualitative assessment. Radiology,2006,239(1):105-112.
[26] Lee DH.Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol,2017,23(4):290-301.
[27] Tang A,Desai A,Hamilton G,et al.Accuracy of MR imaging-
estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology,2015,274(2):416-425.
[28] Noureddin M,Lam J,Peterson MR,et al.Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology,2013,58(6):1930-1940.
[29] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter (CAP):a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis:preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36(11):1825-1835.
[30] Vuppalanchi R,Siddiqui MS,Van Natta ML.et al.Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology,2018,67(1):134-144.
[31] Tribonias G,Margariti E,Tiniakos D,et al.Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol,2014,48(1):59-65.
[32] Verdam FJ,Dallinga JW,Driessen A,et al.Non-alcoholic steatohepatitis:a non-invasive diagnosis by analysis of exhaled breath. J Hepatol,2013,58(3):543-548.
[33] Arasaradnam RP,McFarlane M,Daulton E,et al. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis:early results. J Gastrointestin Liver Dis,2015,24(2):197-201.
[34] Park GJ,Wiseman E,George J,et al.Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol,2011,26(9):1411-1616.

Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[2]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[3]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[4]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[5]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[6]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[7]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[8]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[9]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[10]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[11]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[12]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.
[13]	Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.
[14]	Wang Xinwei, Lyu Ke, Sun Xiao, et al. Effect of selective β3-adrenergic receptor agonist on hepatic oxidative stress and liver fibrosis in rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 384-387.
[15]	Li Caihong, Lian Lingling, Lu Derong. Preliminary trial of ezetimibe combined with atorvastatin in treatment of patient with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 405-408.